This is therefore a comparing of the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation in XBiotech Inc. (NASDAQ:XBIT) and Cellect Biotechnology Ltd. (NASDAQ:APOP). The two are both Biotechnology companies that compete with one another.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellect Biotechnology Ltd.||N/A||0.00||N/A||-0.85||0.00|
We can see in table 1 the earnings per share (EPS), gross revenue and valuation of XBiotech Inc. and Cellect Biotechnology Ltd.
Table 2 provides us the net margins, return on equity and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Cellect Biotechnology Ltd.||0.00%||0%||0%|
Institutional & Insider Ownership
Institutional investors held 4.3% of XBiotech Inc. shares and 0% of Cellect Biotechnology Ltd. shares. 9.5% are XBiotech Inc.’s share held by insiders. On the other hand, insiders held about 54.73% of Cellect Biotechnology Ltd.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Cellect Biotechnology Ltd.||-4.19%||-33.88%||-35.74%||-56.13%||-57.5%||-54.29%|
For the past year XBiotech Inc. has 5.08% stronger performance while Cellect Biotechnology Ltd. has -54.29% weaker performance.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.